Abstract 39P
Background
This study aims to investigate the immunohistochemical expression of HIF-1α, GLUT1, and CA IX in patients with invasive ductal breast cancer (IDC) and assess their correlation with the maximum standardized uptake value of the primary tumor (pSUVmax) and other biological parameters. Additionally, the prognostic significance of pSUVmax, HIF-1α, GLUT1, and CA IX in predicting progression-free survival (PFS) will be evaluated.
Methods
A total of 174 female patients with IDC who underwent pretreatment F-18 FDG PET/CT were enrolled in this study. The pSUVmax was compared with clinicopathological parameters, including estrogen receptor (ER), progesterone receptor (PR), HER2 status, axillary lymph node metastasis (LNM), cancer stage, GLUT1, CA IX, and HIF-1α. The prognostic value of pSUVmax, GLUT1, CA IX, and HIF-1α for PFS was analyzed using the Kaplan-Meier method.
Results
The study revealed that pSUVmax was significantly higher in patients with HIF-1α≥2, GLUT1≥5, and CA IX≥3, compared to patients with HIF-1α<2, GLUT1<5, and CA IX<3 (4.9±4.1 vs. 3.9±3.2, P=0.02; 6.1±4.2 vs. 3.5±3.0, P=0.003; 5.9±4.5 vs. 3.8±3.2, P=0.003). Furthermore, patients with disease progression had significantly higher pSUVmax values than those who remained disease-free (6.4±3.5 vs. 4.1±3.6, P=0.0045). Receiver-operating characteristic (ROC) curve analysis identified optimal cutoff values for predicting PFS as pSUVmax of 6.8, GLUT1 of 5, and CA IX of 3, with corresponding sensitivities and specificities. Kaplan-Meier analysis revealed that pSUVmax ≥6.8 (P=0.0004), GLUT1≥5 (P=0.0005), and CA IX≥3 (P<0.0001) were predictive of recurrence.
Conclusions
The study findings indicate that pSUVmax on pretreatment F-18 FDG PET/CT can serve as a reliable surrogate marker for predicting progression in patients with IDC. Increased FDG uptake is associated with higher expression levels of HIF-1α, GLUT1, and CA IX, indicating the presence of glucose metabolism and hypoxia in breast cancer cells. These biomarkers hold promise for improved cancer detection and prognostication in IDC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract